Trial Outcomes & Findings for Target Engagement for Oxytocin: Dose Ranging Study (NCT NCT02498236)

Last Updated: 2019-01-31

Results Overview

This primary outcome measure is mu suppression recorded during a biological motion task. In this task, participants view point-light walker (PLW) animations of a human; the PLWs were either male or female, happy or sad, or walking towards or away from the viewer. In addition to the humans, there was a control condition which consisted of a circle moving either left or right. In separate blocks, participants had to identify either the gender, the emotion, or intention (i.e., direction) of the walker, or the direction of the circle, while their EEG was recorded. The primary measure was mu activity (8-12 Hz) recorded over 3 central electrodes. Mu suppression was calculated as the log10 transformed ratio of mu power to one of the three human conditions compared to the circle: log10(human/circle). A negative value indicates suppression of mu activity to human walkers vs. circles. We are presenting the mean (SD) of this suppression ratio collapsed over the 3 human conditions.

Recruitment status

COMPLETED

Study phase

Target enrollment

51 participants

Primary outcome timeframe

Baseline, 1 Week

Results posted on

2019-01-31

Participant Flow

Participant milestones

Participant milestones
Measure	8IU Oxytocin Subjects received either 8IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	12IU Oxytocin Subjects received either 12IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	24IU Oxytocin Subjects received either 24IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	36IU Oxytocin Subjects received either 36IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	48IU Oxytocin Subjects received either 48IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	60IU Oxytocin Subjects received either 60IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	72IU Oxytocin Subjects received either 72IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	84IU Oxytocin Subjects received either 84IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.
Overall Study STARTED	6	6	6	6	7	6	7	7
Overall Study Randomized	6	6	6	6	7	6	7	7
Overall Study COMPLETED	5	6	6	6	6	6	6	6
Overall Study NOT COMPLETED	1	0	0	0	1	0	1	1

Reasons for withdrawal

Reasons for withdrawal
Measure	8IU Oxytocin Subjects received either 8IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	48IU Oxytocin Subjects received either 48IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	72IU Oxytocin Subjects received either 72IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	84IU Oxytocin Subjects received either 84IU Oxytocin or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.
Overall Study Did not show for testing	1	0	0	1
Overall Study Equipment failure	0	0	1	0
Overall Study Withdrawal by Subject	0	1	0	0

Baseline Characteristics

Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	8IU Oxytocin n=5 Participants Subjects received either the assigned Oxytocin dose or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	12IU Oxytocin n=6 Participants Subjects received either the assigned Oxytocin dose or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	24IU Oxytocin n=6 Participants Subjects received either the assigned Oxytocin dose or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	36IU Oxytocin n=6 Participants Subjects received either the assigned Oxytocin dose or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	48IU Oxytocin n=6 Participants Subjects received either the assigned Oxytocin dose or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	60IU Oxytocin n=6 Participants Subjects received either the assigned Oxytocin dose or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	72IU Oxytocin n=6 Participants Subjects received either the assigned Oxytocin dose or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	84IU Oxytocin n=6 Participants Subjects received either the assigned Oxytocin dose or placebo 30 minutes prior to study assessments, and a second challenge in the alternative (drug or placebo) condition one week later.	Total n=47 Participants Total of all reporting groups
Age, Continuous	44.6 Years STANDARD_DEVIATION 8.1 • n=5 Participants	45.3 Years STANDARD_DEVIATION 9.2 • n=7 Participants	42.2 Years STANDARD_DEVIATION 11.9 • n=5 Participants	45.5 Years STANDARD_DEVIATION 8.7 • n=4 Participants	43.3 Years STANDARD_DEVIATION 10.0 • n=21 Participants	45.2 Years STANDARD_DEVIATION 9.8 • n=8 Participants	37.2 Years STANDARD_DEVIATION 11.3 • n=8 Participants	43.0 Years STANDARD_DEVIATION 9.8 • n=24 Participants	42.9 Years STANDARD_DEVIATION 9.4 • n=42 Participants
Sex: Female, Male Female	2 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	3 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	2 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	2 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	3 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	2 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	16 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Sex: Female, Male Male	3 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	3 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	4 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	4 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	3 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	5 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	5 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	4 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	31 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	3 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	2 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	10 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Ethnicity (NIH/OMB) Not Hispanic or Latino	4 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	3 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	5 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	6 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	5 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	5 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	4 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	5 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	37 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Race (NIH/OMB) Asian	1 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	3 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Race (NIH/OMB) Black or African American	3 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	2 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	5 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	2 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	3 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	2 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	19 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Race (NIH/OMB) White	1 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	4 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	3 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	4 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	4 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	2 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	4 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	23 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Race (NIH/OMB) More than one race	0 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	1 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	2 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=7 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=5 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=4 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=21 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=8 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=24 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.	0 Participants n=42 Participants • Each row corresponds to a dose of oxytocin. The sum of the participants in each row totals 47, which is the overall analyzed population.
Region of Enrollment United States	5 participants n=5 Participants	6 participants n=7 Participants	6 participants n=5 Participants	6 participants n=4 Participants	6 participants n=21 Participants	6 participants n=8 Participants	6 participants n=8 Participants	6 participants n=24 Participants	47 participants n=42 Participants

PRIMARY outcome

Timeframe: Baseline, 1 Week

Outcome measures

Outcome measures
Measure	8IU Oxytocin n=6 Participants 8 international units (IU) of Oxytocin	12IU Oxytocin n=6 Participants 12 international units (IU) of Oxytocin	24IU Oxytocin n=6 Participants 24 international units (IU) of Oxytocin	36IU Oxytocin n=6 Participants 36 international units (IU) of Oxytocin	48IU Oxytocin n=6 Participants 48 international units (IU) of Oxytocin	60IU Oxytocin n=6 Participants 60 international units (IU) of Oxytocin	72IU Oxytocin n=6 Participants 72 international units (IU) of Oxytocin	84IU Oxytocin n=5 Participants 84 international units (IU) of Oxytocin	Placebo n=47 Participants Placebo condition. This represents the placebo data summarized across all participants regardless as to which dose of oxytocin (OT) they received.
Mu Suppression on EEG	-0.0907 log10 transformed ratio (Hz) Standard Deviation 0.10515	-0.0632 log10 transformed ratio (Hz) Standard Deviation 0.08206	-0.0542 log10 transformed ratio (Hz) Standard Deviation 0.07471	-0.1153 log10 transformed ratio (Hz) Standard Deviation 0.07699	-0.1333 log10 transformed ratio (Hz) Standard Deviation 0.06625	-0.0459 log10 transformed ratio (Hz) Standard Deviation 0.03514	-0.1101 log10 transformed ratio (Hz) Standard Deviation 0.02654	-0.0149 log10 transformed ratio (Hz) Standard Deviation 0.08074	-0.0726 log10 transformed ratio (Hz) Standard Deviation 0.10331

PRIMARY outcome

Timeframe: Baseline, 1 Week

This primary outcome measure is pupil size recorded during a facial affect identification task. In this task, participants view faces portraying happy, afraid, or neutral faces; scrambled images of the faces were also shown. There were 64 trials: 16 trials per each image type. The primary measure was the difference in pupil size averaged over the happy and fearful faces from the scrambled face condition. A positive value indicates greater pupil dilation relative to the scrambled face; a negative value indicates greater pupil constriction relative to the scrambled face. Baseline was defined as the median pupil width 1 second prior to stimulus onset. Pupil sizes during each trial were baseline-corrected by dividing them by baseline median width. Resulting pupil size timecourses were averaged within-subject for each type of stimulus (happy, afraid, neutral, scrambled). The primary dependent variable was computed by taking the average of the change in pupil size between 1 and 3 s.

Outcome measures

Outcome measures
Measure	8IU Oxytocin n=6 Participants 8 international units (IU) of Oxytocin	12IU Oxytocin n=6 Participants 12 international units (IU) of Oxytocin	24IU Oxytocin n=6 Participants 24 international units (IU) of Oxytocin	36IU Oxytocin n=6 Participants 36 international units (IU) of Oxytocin	48IU Oxytocin n=6 Participants 48 international units (IU) of Oxytocin	60IU Oxytocin n=6 Participants 60 international units (IU) of Oxytocin	72IU Oxytocin n=6 Participants 72 international units (IU) of Oxytocin	84IU Oxytocin n=5 Participants 84 international units (IU) of Oxytocin	Placebo n=47 Participants Placebo condition. This represents the placebo data summarized across all participants regardless as to which dose of oxytocin (OT) they received.
Pupil Dilation While Observing Faces	.0074 arbitrary units Standard Deviation .00669	.0347 arbitrary units Standard Deviation .03395	-.0089 arbitrary units Standard Deviation 04525	.0153 arbitrary units Standard Deviation .02317	-.0011 arbitrary units Standard Deviation .02862	.0103 arbitrary units Standard Deviation .01498	.0299 arbitrary units Standard Deviation .03634	.0073 arbitrary units Standard Deviation .03469	.0134 arbitrary units Standard Deviation .03195

Additional Information

Dr. Stephen R. Marder

University of California, Los Angeles

Phone: 3104783711

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place